Beta Drugs Q1FY27 Revenue Jumps 25% to ₹125.55 Crore; Net Profit Up 41%
Beta Drugs reported Q1FY27 consolidated sales of ₹125.55 crore, up 25.3% YoY. Net profit rose 40.92% to ₹16.5 crore. EBITDA (excl. other income) was ₹27.37 crore, up 38.9% YoY. Branded oncology and CMO segments showed strong growth. The company expects 20-25% consolidated growth for FY27.
The announcement details strong financial performance with substantial growth in key metrics and provides a positive outlook for future growth, which is material to investors.
The company reported significant year-on-year growth in revenue, net profit, and EBITDA, along with positive commentary on future growth prospects and strategic initiatives.
Beta Drugs Limited announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company reported a consolidated total sales of ₹125.55 crore for Q1FY27, marking a significant 25.3% increase from ₹100.2 crore in the corresponding quarter of the previous fiscal year. Total revenues stood at ₹127.13 crore.
The company witnessed strong performance across its business segments. Branded oncology sales grew by 47% year-on-year to ₹33.0 crore, driven by improved performance of existing products and new launches. The CMO business also showed robust growth of 41% year-on-year, attributed to strong customer traction and new proprietary NDDS product launches. Exports contributed ₹17.2 crore in Q1FY27 and are expected to accelerate growth in the remainder of FY27.
Consolidated EBITDA (excluding other income) grew by 38.9% year-on-year to ₹27.37 crore, with EBITDA margins at 21.80%. This improvement was driven by higher Gross Margins (56.6% in Q1FY27 vs. 50.4% in Q1FY26) due to a favorable change in sales mix towards branded businesses. Net profit for the quarter surged by 40.92% to ₹16.5 crore, compared to ₹11.7 crore in Q1FY26. This increase was primarily due to reduced finance costs associated with the conversion of CCDs issued in November 2024.
Looking ahead, Beta Drugs reiterates its vision for 2030, targeting accelerated growth and higher margins, with own branded products and exports expected to contribute over 80% of the total turnover. The company is on track to deliver a 20-25% growth on a consolidated basis for FY27. Investments in R&D are expected to yield a robust pipeline of NDDS products for launch in FY27 and FY28, with a focus on being a first-to-launch player in India.
What to do with a filing like this
Beta Drugs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Beta Drugs Limited. Read the original for the full detail.